News · 26 weeks85+177%
2025-12-282026-06-21
Mix6390d
- Other19(30%)
- Market17(27%)
- Insider17(27%)
- SEC Filings9(14%)
- M&A1(2%)
Latest news
25 items- PRCosmos Health Signs Agreement to Deploy Artificial Intelligence (AI)-Powered Call Center to Optimize Order Intake, Customer Communications, and Operating EfficiencyCHICAGO, June 23, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has signed an agreement to deploy an Artificial Intelligence (AI)-powered call center to support customer communications, including order intake and routine support functions, marking the latest step in the Company’s ongoing integration of AI across its operations. Under the agreement, the Company’s wholly owned pharmaceutical distribution subsidiary, CosmoFarm S.A. ("CosmoFarm"), will deploy an AI-powered voice and communications platform to manage and enhance its customer communications. The
- PRCosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual ProfitCumulative orderbook of over 25 million units secured through wholly owned subsidiary Cana Laboratories across multiple EU and international partners.Multi-year agreements extending up to 10 years provide recurring revenue and long-term cash flow visibility.Diversified across nine therapeutic categories, reducing dependence on any single product or partner.Produced at Cana’s 54,000 sq. ft., EU-GMP-licensed, EMA-certified Athens facility, following an approximately $5.5 million upgrade program and a new ACG capsule-filling line.Division expected to generate over $10 million in recurring annual profit at full capacity. CHICAGO, June 22, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos H
- PRCosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility CapacityCHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, CosmoFarm S.A. ("CosmoFarm"), delivered record revenue of over $15 million in the second quarter of 2026, representing an annualized run-rate of over $60 million. CosmoFarm added more than 80 new pharmacies to its distribution network during the period, continuing the strong customer growth that has made it one of the leading pharmaceutical wholesalers in the greater Athens area. To support this accelerating growth, Cosmos Health is increasing capital expenditure at C
- PRCosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological ProductsCHICAGO, June 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that, through its wholly owned subsidiary Cana Laboratories S.A. ("Cana"), it has entered into a five-year contract manufacturing agreement with Pharmex S.A. ("Pharmex") to produce three pharmaceutical products. Under the agreement, Cana will manufacture the following products for Pharmex at its EU-GMP-licensed, EMA-certified facility, with combined volumes of approximately 2.86 million units over the five-year term. ProductActive IngredientPharmaceutical FormAnnual UnitsFive-Year TotalBETAFUSIN®Betame
- INSIDERChief Financial Officer Terzis Georgios bought $42,000 worth of shares (168,135 units at $0.25), increasing direct ownership by 8% to 2,235,398 units (SEC Form 4)4 - Cosmos Health Inc. (0001474167) (Issuer)
- PRCosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross ProfitCHICAGO, June 15, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided an update on its United States market entry through the "18 Series," a science-driven nutraceutical platform built on proprietary ingredients, published clinical research, and exact clinical dosing, and disclosed projected annualized revenue and implied gross profit for four of its launched products. Since launching the 18 Series in the U.S., Cosmos Health has introduced five products: Noor18™, Liv18™, Cur18™, Fort18™, and Oliv18™ — four of which currently have disclosed projections. The Company has o
- PRCosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of MedicinesCHICAGO, June 12, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly-owned subsidiary, Cana Laboratories ("Cana"), has received new contract manufacturing orders from Nassington and Verisfield for a combined 253,657 units across a range of medicines and other pharmaceutical products. Under the orders, Cana will manufacture Gritse oral solution 0.4 mg/ml (bottle x 150 ml); Gritse forte oral solution 2 mg/ml (bottle x 50 ml); Gritse forte oral solution 4 mg/ml (bottle x 50 ml); Fungofort cutaneous spray, solution (30 ml); Paco-4 tablets (250+250+65+35 mg);
- INSIDERChief Executive Officer Siokas Grigorios bought $45,000 worth of shares (218,447 units at $0.21), increasing direct ownership by 2% to 13,481,808 units (SEC Form 4)4 - Cosmos Health Inc. (0001474167) (Issuer)
- PRCosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross ProfitStrong sales momentum: across the UK and Greece, the brands' first two markets.Over $1.5 million in sales: C-Scrub and C-Sept have generated over $1.5 million in combined annualized sales across the United Kingdom and Greece.High-margin proprietary pillar: gross margins above 70%, among the most attractive in Cosmos Health's portfolio.EU expansion: targeting annual revenue rising to $7.4 million with gross profit of approximately $5.3 million within three years.Potential upside: the target may be revised upward as C-Scrub launches into the animal healthcare market. CHICAGO, June 12, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified
- INSIDERChief Executive Officer Siokas Grigorios bought $160,000 worth of shares (701,447 units at $0.23), increasing direct ownership by 6% to 13,263,361 units (SEC Form 4)4 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERDirector Karkantzos Theodoros Christos was granted 20,000 shares, increasing direct ownership by 133% to 35,000 units (SEC Form 4)4 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERDirector Hoidas John James was granted 20,000 shares, increasing direct ownership by 67% to 50,000 units (SEC Form 4)4 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERSecretary Demetriades Demetrios G. was granted 20,000 shares, increasing direct ownership by 57% to 55,000 units (SEC Form 4)4 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERDirector Bhutawala Suhel was granted 20,000 shares, increasing direct ownership by 44% to 65,000 units (SEC Form 4)4 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERDirector Aslidis Anastasios was granted 40,000 shares, increasing direct ownership by 67% to 100,000 units (SEC Form 4)4 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERChief Financial Officer Terzis Georgios was granted 850,000 shares, increasing direct ownership by 70% to 2,067,263 units (SEC Form 4)4 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERChief Executive Officer Siokas Grigorios was granted 2,350,000 shares, increasing direct ownership by 23% to 12,561,914 units (SEC Form 4)4 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERSiokas Grigorios acquired $1,450 worth of shares (1,450,000 units at $0.00), decreasing direct ownership by 93% to 490,000 units (SEC Form 5)5 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERAslidis Anastasios acquired $20 worth of shares (20,000 units at $0.00), increasing direct ownership by 50% to 60,000 units (SEC Form 5)5 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERTerzis Georgios acquired $490 worth of shares (490,000 units at $0.00), increasing direct ownership by 67% to 1,217,263 units (SEC Form 5)5 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERDemetriades Demetrios G. acquired $15 worth of shares (15,000 units at $0.00), increasing direct ownership by 75% to 35,000 units (SEC Form 5)5 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERHoidas John James acquired $15 worth of shares (15,000 units at $0.00), increasing direct ownership by 100% to 30,000 units (SEC Form 5)5 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERKarkantzos Theodoros Christos acquired $15 worth of shares (15,000 units at $0.00) (SEC Form 5)5 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERBhutawala Suhel acquired $15 worth of shares (15,000 units at $0.00), increasing direct ownership by 50% to 45,000 units (SEC Form 5)5 - Cosmos Health Inc. (0001474167) (Issuer)
- PRCosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product PortfolioDoc Pharma financial profile: approximately $24 million asset base, approximately $6.7 million in average annual revenue and approximately $3.2 million in average annual gross profit.Immediately accretive: expected to support margin expansion, profitability, and cash flow.Deepens vertical integration: expected to drive synergies, optimized production, economies of scale, expanded capacity, and a strengthened R&D engine.State-of-the-art production plant: GMP-licensed, approximately 59,000 square feet, built to the highest European standards, providing a clear growth avenue.Manufacturing excellence: a broad range of dosage forms, certified to GMP, ISO, Kosher, and Halal standards, with site re
COSM FAQ
5 questionsWhat does Cosmos Health Inc. do?
Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and...Where does COSM stock trade?
Cosmos Health Inc. (COSM) is listed on NASDAQ.What sector and industry is COSM in?
Cosmos Health Inc. operates in the Health Care sector, Other Pharmaceuticals industry.What companies are similar to COSM?
Notable peers in the same industry include MCK (McKesson Corporation), COR (Cencora Inc.), CAH (Cardinal Health Inc.), ABC (AmerisourceBergen Corporation), CVET (Covetrus Inc.). Compare COSM side-by-side with any of them on Quantisnow.How can I track COSM on Quantisnow?
Quantisnow aggregates Cosmos Health Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow COSM to receive live email and push alerts on every new disclosure.